Page 94 - Read Online

Page 10 of 11 Yaroustovsky et al. Vessel Plus 2019;3:9 I http://dx.doi.org/10.20517/2574-1209.2019.02

Copyright
© The Author(s) 2019.

REFERENCES
1. Sokolov AA, Alexandrova OY, Kashtalap VV, Barbarash OL, Yezhov MV. Guidelines on the medical care organization to the
patients with hereditary atherogenic lipid disorders in the Regions of Russia (Joint project of the national society for the research
on atherosclerosis and non-profit partnership “The national council of experts on rare diseases”). Bulletin Contempor Clin Med
2017;10:83-8. (in Russia).
2. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe epidemiological update 2015. Eur Heart J
2015;36:2696-705.
3. Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: current view and future perspective on
lipoprotein modification treatment. Neth Heart J 2017;25:231-42.
4. Klose G, Laufs U, Marz W, Windler E. Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int
2014;111:523-9.
5. Orsó E, Ahrens N, Kilalić D, Schmitz G. Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined
cardiovascular risk factors. Atheroscler Suppl 2009;10:74-8.
6. Sobenin IA, Galitsyna EV, Grechko AV, Orekhov AN. Small dense and desialylated low density lipoprotein in diabetic patients. Vessel
Plus 2017;1:29-37.
7. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198-208.
8. Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, et al. Rationale and design of MultiSELECt: a European multicenter study
on the effect of Lipoprotein(a) elimination by lipoprotein apheresis on cardiovascular outcomes. Atheroscler Suppl 2017;30:180-6.
9. Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein(a). Curr Opin Lipidol 2014;25:452-60.
10. Lamon-Fava S, Diffenderfer MR, Marcovina SM. Lipoprotein(a) metabolism. Curr Opin Lipidol 2014;25:189-93.
11. Pokrovsky SN, Afanasieva OI, Safarova MS, Balakhonova TV, Matchin YG, et al. Specific Lp(a) apheresis: a tool to prove
lipoprotein(a) atherogenicity. Atheroscler Suppl 2017;30:166-73.
12. Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and
recent advances. Curr Atheroscler Rep 2015;17:465.
13. Abramyan MV. Possibilities of LDL-apheresis in the complex treatment of atherosclerosis. Creative Cardiology 2007;1-2:208-19. (in
Russia)
14. Makino H, Tamanaha T, Harada-Shiba M. LDL apheresis in Japan. Transfus Apher Sci 2017;56:677-81.
15. Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, et al. Toward an international consensus-integrating lipoprotein apheresis
and new lipid-lowering drugs. J Clin Lipidol 2017;11:858-71.
16. Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). J Lipid Res 2016;57:1751-7.
17. de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. Homozygous cutaneo-tendinous forms of hypercholesteremic
xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment. Bull Mem Soc Med Hop Paris
1967;118:1377-402.
18. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet
1975;1:1208-11.
19. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, et al. Assessment of longterm plasma exchange for familial
hypercholesterolaaemia. Br Heart J 1980;43:680-8.
20. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, et al. Association between change in high density lipoprotein cholesterol
and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.
21. Nenseter MS, Bogsrud MP, Græsdal A, Narverud I, Halvorsen B, et al. LDL-apheresis affects markers of endothelial function in patients
with homozygous familial hypercholesterolemia. Thromb Res 2012;130:823-5.
22. Derfler K, Steiner S, Sinzinger H. Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. Wien Klin
Wochenschr 2015;127:655-63.
23. Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl 2017;30:1-8.
24. Winters JL. Lipid apheresis, indications, and principles. J Clin Apher 2011;26:269-75.
25. Julius U. Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis 2018;5:27.
26. Kozik-Jaromin J, Röseler E, Heigl F, Spitthöver R, Ringel J, et al. Safety aspects of lipidapheresis using DALI and MONET -
multicenter observational study. Atheroscler Suppl 2017;30:225-31.
27. Temizhan A, Cetin EH, Cetin MS, Tak BT. Comparison of two lipid apheresis systems in patients with homozygous familial
hypercholesterolemia: a single center 3-year experience. JACC 2018;71:1780.
28. Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration-safe and effective methodology to perform lipid-apheresis. Transfus
Apher Sci 2004;30:245-54.
29. van Buuren F, Kreickmann S, Horstkotte D, Kottmann T, Mellwig KP. HELP apheresis in hypercholesterolemia and cardiovascular
disease: efficacy and adverse events after 8,500 procedures. Clin Res Cardiol Suppl 2012;7:24-30.